Dehn, S.* ; Burkhard, R.* ; Leyens, J.* ; Kaiser, T.* ; Brandimarte, S.* ; Heiligensetzer, D.* ; Koppensteiner, H. ; Bajoghli, B.* ; Hailfinger, S.* ; Schilbach, K.* ; Schindler, M.
HIV-1 manipulates CD96 on CD4+ T cells to subvert antiviral immunity.
Sci. Adv. 11:eadx7485 (2025)
HIV-1 evades immune responses by modulating plasma membrane receptors. Using a flow cytometry-based screening, we profiled 332 surface receptors on HIV-1-infected primary CD4+ T cells and identified 23 down-regulated receptors, including known targets such as CD4, MHCI, CCR7, and CD62L. CD96, an inhibitory natural killer (NK) cell receptor poorly studied in human CD4+ T cells, was markedly down-regulated. This modulation, mediated by the viral proteins Nef and Vpu, surpassed that of other NK-associated receptors such as CD155 and NTB-A and is conserved across lentiviruses. CD96Hi CD4+ T cells exhibited a proinflammatory TH1/TH17 phenotype characterized by IFN-γ and IL-17 secretion and displayed impaired migration in vivo. Furthermore, CD96 ligation enhanced IFN-γ release upon viral peptide stimulation and promoted the secretion of TH1/TH17-associated cytokines. Our findings suggest that CD96 regulates antiviral immune responses and maintains proinflammatory properties in CD4+ T cells. Thus, its down-regulation represents a previously unknown HIV-1 immune evasion strategy, with implications for exploiting CD96 as immunotherapeutic target.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Human-immunodeficiency-virus; Down-modulation; Type-1 Nef; Surface Expression; Vpu; Receptor; Protein; Activation; Adhesion; Tigit
Keywords plus
Language
english
Publication Year
2025
Prepublished in Year
0
HGF-reported in Year
2025
ISSN (print) / ISBN
2375-2548
e-ISSN
2375-2548
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 11,
Issue: 36,
Pages: ,
Article Number: eadx7485
Supplement: ,
Series
Publisher
American Association for the Advancement of Science (AAAS)
Publishing Place
Washington, DC [u.a.]
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Immune Response and Infection
PSP Element(s)
G-502700-006
Grants
Helmholtz Center Munich
University Hospital Tubingen
Deutsche Forschungsgemeinschaft
Copyright
Erfassungsdatum
2025-10-17